Matthias Lechmann

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11771797/publications.pdf

Version: 2024-02-01

		471509	839539
18	1,407	17	18
papers	citations	h-index	g-index
18	18	18	1748
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	CD83 on dendritic cells: more than just a marker for maturation. Trends in Immunology, 2002, 23, 273-275.	6.8	214
2	Aptamer-Facilitated Biomarker Discovery (AptaBiD). Journal of the American Chemical Society, 2008, 130, 9137-9143.	13.7	181
3	The Extracellular Domain of CD83 Inhibits Dendritic Cell–mediated T Cell Stimulation and Binds to a Ligand on Dendritic Cells. Journal of Experimental Medicine, 2001, 194, 1813-1821.	8.5	168
4	Prevention and Treatment of Experimental Autoimmune Encephalomyelitis by Soluble CD83. Journal of Experimental Medicine, 2004, 200, 345-351.	8.5	133
5	Thymic Stromal Lymphopoetin-Induced Expression of the Endogenous Inhibitory Enzyme SLPI Mediates Recovery from Colonic Inflammation. Immunity, 2011, 35, 223-235.	14.3	97
6	Role of CD83 in the Immunomodulation of Dendritic Cells. International Archives of Allergy and Immunology, 2002, 129, 113-118.	2.1	92
7	The CD83 Molecule – An Important Immune Checkpoint. Frontiers in Immunology, 2020, 11, 721.	4.8	86
8	Herpes Simplex Virus Type 1 Induces CD83 Degradation in Mature Dendritic Cells with Immediate-Early Kinetics via the Cellular Proteasome. Journal of Virology, 2007, 81, 6326-6338.	3.4	73
9	Topical Application of Soluble CD83 Induces IDO-Mediated Immune Modulation, Increases Foxp3+ T Cells, and Prolongs Allogeneic Corneal Graft Survival. Journal of Immunology, 2013, 191, 1965-1975.	0.8	60
10	FAM13A is associated with non-small cell lung cancer (NSCLC) progression and controls tumor cell proliferation and survival. Oncolmmunology, 2017, 6, e1256526.	4.6	44
11	The soluble form of CD83 dramatically changes the cytoskeleton of dendritic cells. Immunobiology, 2004, 209, 129-140.	1.9	43
12	CD83 expression is essential for Treg cell differentiation and stability. JCI Insight, 2018, 3, .	5.0	42
13	Overexpression, Purification, and Biochemical Characterization of the Extracellular Human CD83 Domain and Generation of Monoclonal Antibodies. Protein Expression and Purification, 2002, 24, 445-452.	1.3	39
14	CD83 is a dimer: Comparative analysis of monomeric and dimeric isoforms. Biochemical and Biophysical Research Communications, 2005, 329, 132-139.	2.1	37
15	The CD83 reporter mouse elucidates the activity of the CD83 promoter in B, T, and dendritic cell populations (i) in vivo (i). Proceedings of the National Academy of Sciences of the United States of America, 2008, 105 , 11887 - 11892 .	7.1	36
16	Murine CD83-positive T cells mediate suppressor functions in vitro and in vivo. Immunobiology, 2015, 220, 270-279.	1.9	28
17	Opposing functions of thymic stromal lymphopoietin–responsive basophils and dendritic cells in a mouse model of atopic dermatitis. Journal of Allergy and Clinical Immunology, 2016, 138, 1443-1446.e8.	2.9	21
18	Determination of the inhibitory activity and biological half-live of soluble CD83: Comparison of wild type and mutant isoforms. Immunobiology, 2006, 211, 449-453.	1.9	13